Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)

PHASE4UnknownINTERVENTIONAL

Enrollment

2,000

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2015

Conditions

Coronary Artery Disease

Interventions

DEVICE

XIENCE PRIMETM everolimus-eluting coronary stent

"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul